The US nonprofit founded by the UK's Wellcome Trust will fund collaborative research projects to build multiscale and multimodal "tissue time machines."
Fresh off a name change, the company last week introduced a monitoring platform for new SARS-CoV-2 variants that alerts diagnostic test makers to potential problems.
The Taiwan-based startup aims to publish data showing the instrument's prognostic value in colorectal cancer, as well as launch a new version, by this summer.
